ACORQ — Acorda Therapeutics Balance Sheet
0.000.00%
- $0.02m
- $182.13m
- $117.63m
- 41
- 63
- 17
- 35
Annual balance sheet for Acorda Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 126 | 71.4 | 45.6 | 37.5 | 30 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 22.1 | 20.2 | 17 | 13.9 | 17.3 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 201 | 221 | 102 | 82.1 | 74.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 166 | 25.7 | 11.1 | 7.89 | 6.3 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 800 | 633 | 455 | 396 | 109 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 86.4 | 137 | 54 | 38 | 228 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 489 | 395 | 304 | 302 | 266 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 311 | 238 | 151 | 93.6 | -158 |
Total Liabilities & Shareholders' Equity | 800 | 633 | 455 | 396 | 109 |
Total Common Shares Outstanding |